Condition,Type,Comment,Mutation
10F,Accessory,"L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV.",L10F
10IV,Other,"L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.",L10IV
10RY,Other,"L10R/Y are rare, non-polymorphic PI-selected mutations. Their effects on PI susceptibility have not been well studied.",L10RY
11IL,Other,V11I is a relatively non-polymorphic accessory mutation selected in patients receiving DRV. It is included in the Tibotec DRV genotypic susceptibility score. V11L is a nonpolymorphic PI-selected mutation associated with reduced DRV and FPV susceptibility when it occurs in combination with other PI-resistance mutations.,V11I
20I,Other,"K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility.",K20I
20MV,Other,"K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied.",K20MV
20R,Other,K20R is a highly polymorphic PI-selected accessory mutation.,K20R
20T,Accessory,K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV.,K20T
23I,Accessory,L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance.,L23I
24FM,Accessory,L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV. L24F/M are uncommon non-polymorphic PI-selected mutations. L24F has a susceptibility profile similar to L24I.,L24FM
24I,Accessory,L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV.,L24I
30N,Major,D30N is a non-polymorphic mutation that causes high-level resistance to NFV.,D30N
32I,Major,V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score.,V32I
33F,Accessory,"L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score.",L33F
33Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,33Insertion
34Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,34Insertion
35Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,35Insertion
36Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,36Insertion
37Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,37Insertion
38Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,38Insertion
39Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,39Insertion
40Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,40Insertion
41Insertion,Other,Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility.,41Insertion
43T,Accessory,K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score.,K43T
46IL,Major,"M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV.",M46IL
46V,Accessory,"M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46V is a rare non-polymorphic PI-selected mutation that has not been well studied.",M46V
47A,Major,I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV.,I47A
47V,Major,I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47V is included in the Tibotec DRV genotypic susceptibility score.,I47V
48ASTQL,Major,"G48V is a non-polymorphic mutation selected by SQV and, less often, by IDV and LPV. It confers high-level resistance to SQV, intermediate resistance to ATV, and low-level resistance to NFV, IDV and LPV. G48M is a non-polymorphic mutation selected in viruses with multiple PI-resistance mutations. Its effects appear to be similar to those of G48V. G48A/S/T/Q are rare non-polymorphic mutations selected in viruses with multiple PI-resistance mutations.",G48ASTQL
48M,Major,"G48V is a non-polymorphic mutation selected by SQV and, less often, by IDV and LPV. It confers high-level resistance to SQV, intermediate resistance to ATV, and low-level resistance to NFV, IDV and LPV. G48M is a non-polymorphic mutation selected in viruses with multiple PI-resistance mutations. Its effects appear to be similar to those of G48V.",G48M
48V,Major,"G48V is a non-polymorphic mutation selected by SQV and, less often, by IDV and LPV. It confers high-level resistance to SQV, intermediate resistance to ATV, and low-level resistance to NFV, IDV and LPV.",G48V
50L,Major,I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs.,I50L
50V,Major,"I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. It is included in the Tibotec DRV genotypic susceptibility score.",I50V
53L,Accessory,"F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV.",F53L
54ATS,Major,I54A/T/S are non-polymorphic PI-selected mutations that occur almost exclusively in viruses with multiple PI-resistance mutations. I54A/T/S are associated with reduced susceptibility to each of the PIs except DRV.,I54ATS
54LM,Major,I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility score.,I54ML
54V,Major,I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV.,I54V
58E,Accessory,Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs.,Q58E
71IL,Other,"A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations.",A71I
71IL,Other,"A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations.",A71L
71TV,Other,"A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.",A71V
71TV,Other,"A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.",A71T
73STCADV,Accessory,"G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations.",G73STCA
74P,Accessory,T74P is a non-polymorphic PI-selected accessory mutation that occurs primarily in viruses from patients who have received multiple PIs. It is associated with reduced susceptibility to each of the PIs. It is included in the Boehringer-Ingelheim TPV and Tibotec DRV genotypic susceptibility scores.,T74P
74S,Other,T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes.,T74S
76V,Major,"L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score.",L76V
82A,Major,V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV.,V82A
82C,Major,V82C is an uncommon non-polymorphic mutation that occurs primarily in viruses with multiple other PI-resistance mutations. Its effects on PI susceptibility have not been well studied.,V82C
82F,Major,V82F is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs.,V82F
82I,Other,V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses.,V82I
82L,Major,V82L is an uncommon non-polymorphic mutation selected by TPV. It reduces TPV susceptibility but its effects on other PIs have not been well studied.,V82L
82M,Major,"In most subtypes, V82M is a 2-base-pair mutation that develops in viruses with multiple other PI-resistance mutations. In subtype G, V82M is a 1-base-pair mutation. V82M reduces susceptibility to IDV, LPV and possibly other PIs.",V82M
82TS,Major,V82T/S are non-polymorphic PI-selected mutations. They are associated with reduced susceptibility to each of the PIs except DRV. V82T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score.,V82TS
83D,Accessory,N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV.,N83D
84AC,Major,I84A is an extremely rare non-polymorphic PI-selected substrate-cleft mutation associated with high-level resistance to each of the PIs except possibly DRV. I84C is an extremely rare non-polymorphic PI-selected mutation associated with varying degrees of reduced susceptibility to each of the PIs.,I84AC
84V,Major,"I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV.",I84V
85V,Other,"I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility.",I85V
88D,Accessory,N88D is a non-polymorphic mutation selected by NFV usually in combination with D30N. It reduces NFV susceptibility and may cause low-level cross-resistance to ATV and SQV.,N88D
88S,Major,"N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV.",N88S
88TG,Major,N88G/T are extremely rare non-polymorphic PI-selected mutations that reduce susceptibility to NFV and ATV.,N88TG
89VT,Accessory,"L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied.",L89VT
90M,Major,L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV.,L90M
90I,Other,"V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility.",V90I
98G,NNRTI,A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.,A98G
100I,NNRTI,"L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N.",L100I
100V,NNRTI,"L100I is a non-polymorphic mutation that usually occurs with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR and possibly DOR. L100V is a rare non-polymorphic mutation with low / intermediate resistance to EFV, NVP, and RPV.",L100V
101E,NNRTI,"K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility.",K101E
101H,NNRTI,"K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known.",K101H
101NAT,Other,K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.,K101NAT
101P,NNRTI,"K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility.",K101P
101Q,Other,K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance.,K101Q
103EQ,NNRTI,K103E/Q are rare mutations that have not been associated with reduced NNRTI susceptibility.,K103EQ
103H,NNRTI,K103H is a rare non-polymorphic mutation that causes high-level resistance to NVP and EFV.,K103H
103N,NNRTI,K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility.,K103N
103R,Other,"K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.",K103R
103S,NNRTI,"K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N.",K103S
103T,NNRTI,K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility.,K103T
106A,NNRTI,"V106A is a non-polymorphic mutation that causes high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR.",V106A
106I,NNRTI,V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227.,V106I
106M,NNRTI,V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.,V106M
108I,NNRTI,"V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV.",V108I
132ML,Other,"I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied.",I132ML
138A,NNRTI,E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.,E138A
138K,NNRTI,"E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR and possibly to DOR.",E138K
138QG,NNRTI,"E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known.",E138QG
138R,NNRTI,E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV and possibly to NVP and EFV. Its effect on DOR is not known.,E138R
179DE,NNRTI,V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological response to a first-line EFV-containing regimen.,V179DE
179F,NNRTI,"V179F is a non-polymorphic mutation frequently selected in patients receiving ETR. It nearly always occurs in combination with Y181C. Alone V179F has little effect on NNRTI susceptibility. In combination with Y181C, however, it is associated with high-level ETR and RPV resistance. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score.",V179F
179I,Other,"V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility.",V179I
179L,NNRTI,V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert.,V179L
179T,NNRTI,"V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score.",V179T
181C,NNRTI,"Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced response to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility.",Y181C
181FSG,NNRTI,Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.,Y181FSG
181IV,NNRTI,"Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized.",Y181IV
188C,NNRTI,"Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV. It appears to cause little if any reduction in susceptibility to RPV, ETR, or DOR.",Y188C
188F,NNRTI,Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.,Y188F
188H,NNRTI,"Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV. It appears to cause little if any reduction in susceptibility to RPV, ETR, or DOR.",Y188H
188L,NNRTI,"Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR.",Y188L
190A,NNRTI,G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility.,G190A
190CTV,NNRTI,"G190C/T/V are rare non-polymorphic mutations that cause high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known.",G190CTV
190EQ,NNRTI,"G190E is a non-polymorphic mutation that causes intermediate to high-level resistance to each of the NNRTIs. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known.",G190EQ
190R,Other,G190R is strongly suspicious for being an artifact of APOBEC-mediated G-to-A hypermutation. It has not been associated with reduced NNRTI susceptibility.,G190R
190S,NNRTI,G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility.,G190S
221Y,NNRTI,"H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C.",H221Y
225H,NNRTI,"P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility.",P225H
227C,NNRTI,"F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or high-level reductions in susceptibility to NVP, EFV, ETR, and RPV.",F227C
227ILV,NNRTI,F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.,F227ILV
230I,NNRTI,M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious.,M230I
230L,NNRTI,"M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs.",M230L
234I,NNRTI,"L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been well characterized.",L234I
236L,NNRTI,P236L is a non-polymorphic mutation that has been selected in vitro by DOR and been associated with possible low-level reductions in susceptibility in vitro.,P236L
238R,Other,K238R is a common polymorphism that does not reduce NNRTI susceptibility.,K238R
238TN,NNRTI,"K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility.",K238TN
318F,NNRTI,Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR and in combination with other mutations it has been associated with high-level reductions in DOR susceptibility. Its effect on DOR susceptibility when it occurs alone has not been studied.,Y318F
348I,NNRTI,N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.,N348I
40F,NRTI,"E40F is a non-polymorphic accessory mutation selected by AZT and d4T. It usually occurs in combination with M41L, L210W and T215Y. In this context it is associated with reduced susceptibility to each of the NRTIs.",E40F
41I,Other,M41I is usually an artifact resulting from APOBEC3G-mediated hypermutation.,M41I
41L,NRTI,"M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility.",M41L
44AD,NRTI,E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.,E44AD
62V,NRTI,A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic.,A62V
65E,NRTI,"K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT. K65E is an extremely rare NRTI-selected mutation with markedly reduced replication fitness.",K65R
65N,NRTI,"K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT. K65N is a rare mutation with similar but less pronounced effects on NRTI susceptibility than K65R.",K65R
65R,NRTI,"K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT.",K65R
67Deletion,NRTI,"Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex.",67Deletion
67GESTH,NRTI,"D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs.",D67GESTH
67N,NRTI,"D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF.",D67N
68Deletion,NRTI,"Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex. Deletions at codon 68 are extremely rare and less well characterized.",68Deletion
68G,Other,S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R.,S68G
69Deletion,NRTI,"Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex.",69Deletion
69D,NRTI,T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T.,T69D
69G,NRTI,T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations.,T69G
69N,Other,"T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT.",T69N
69SAIE,Other,T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied.,T69SAIE
69Insertion,NRTI,"Amino acid insertions between codons 67 and 70 are by convention assigned to codon 69. Together with TAMs, they are associated with high-level resistance to AZT, d4T, ddI, ABC and TDF and intermediate to 3TC and FTC.",69Insertion
70Deletion,NRTI,"Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex.",70Deletion
70EG,NRTI,"K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT.",K70EG
70QNST,NRTI,"K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G.",70QNST
70R,NRTI,"K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF.",K70R
74VI,NRTI,L74V/I cause high-level resistance to ddI and intermediate resistance to ABC.,L74VI
75I,NRTI,V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain.,V75I
75M,NRTI,"V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance.",V75M
75SA,NRTI,V75S/A are non-polymorphic mutations that appear to reduce susceptibility to d4T and ddI.,V75SA
75T,NRTI,V75T causes high-level d4T resistance and intermediate ddI resistance.,V75T
77L,NRTI,"F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain.",F77L
115F,NRTI,Y115F causes intermediate resistance to ABC and low-level resistance to TDF.,Y115F
116Y,NRTI,F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M.,F116Y
118I,Other,V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs.,V118I
151L,NRTI,"Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M.",Q151M
151M,NRTI,"Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC.",Q151M
184VI,NRTI,"M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication.",M184VI
210W,NRTI,"L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF.",L210W
215F,NRTI,"T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.",T215F
215SCDEIVALN,NRTI,"T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F.",215SCDEIVALN
215Y,NRTI,"T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF.",T215Y
219NR,NRTI,K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs.,K219NR
219QE,NRTI,K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T.,K219QE
219W,NRTI,K219W is an uncommon NRTI-selected mutation.,K219W
49G,Accessory,A49G is a rare nonpolymorphic IN mutation that has been reported in combination with one or more INSTI-resistance mutations in two persons receiving DTG.,A49G
50I,Other,M50I is a polymorphic mutation selected in vitro by DTG and BIC in combination with R263K. It appears to contribute to reduced DTG susceptibility in combination with R263K.,M50I
51Y,Accessory,H51Y is a rare non-polymorphic accessory mutation selected in patients receiving RAL and EVG and in vitro by DTG. H51Y minimally reduces EVG and possibly CAB susceptibility.,H51Y
66A,Major,"T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderate reduction in EVG susceptibility but does not appear to reduce susceptibility to other INSTIs.",T66A
66I,Major,"T66I is a non-polymorphic mutation selected in patients receiving EVG, RAL, and DTG. It reduces EVG susceptibility about 10-fold but does not reduce susceptibility to other INSTIs.",T66I
66K,Major,"T66K is a non-polymorphic mutation selected in patients receiving EVG. It is associated with high-level EVG resistance, intermediate/high-level RAL resistance, and low-level DTG and CAB resistance. Its effect on BIC is not known.",T66K
74MIF,Other,"L74M is a polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 5% of patients depending on subtype. L74I occurs in 4% to 40% of patients depending on subtype. L74I is the consensus amino acid for subtype A6 and does not appear to be selected by INSTI therapy. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, L74M and possibly L74I reduce susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations.",L74MIF
92G,Major,"E92G is a rare non-polymorphic mutation that has been selected in patients receiving EVG. It moderately reduces EVG susceptibility but does not reduce susceptibility to RAL, DTG, or BIC.",E92G
92Q,Major,E92Q is a common non-polymorphic mutation selected in patients receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It is selected in vitro by DTG and reduces DTG susceptibility ~1.5-fold. It does not appear to reduce BIC susceptibility.,E92Q
92V,Major,E92V is a rare non-polymorphic mutation selected in vitro by an investigational INSTI. It causes high-level resistance to EVG and intermediate resistance to RAL.,E92V
95K,Accessory,"Q95K is a non-polymorphic INSTI-selected mutation. Alone, it has little if any effect on INSTI susceptibility.",Q95K
97A,Accessory,"T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs.",T97A
118R,Major,G118R is a rare non-polymorphic mutation selected in patients receiving RAL and DTG and in vitro by DTG. Depending on the mutational context it causes 3 to 30-fold reduced susceptibility to each of the INSTIs.,G118R
119R,Other,"S119R is a polymorphic mutation that is weakly selected by INSTIs usually in combination with several major INSTI-associated DRMs. Alone, it has little, if any effect, on INSTI susceptibility .",S119R
121C,Other,"F121C is a rare mutation; preliminary data suggests it confers high level phenotypic resistance to RAL, EVG, and CAB.",F121C
121Y,Major,"F121Y is a non-polymorphic mutation selected in vitro by RAL and EVG. It has been reported rarely in patients receiving RAL. It causes intermediate to high-level reductions in RAL and EVG susceptibility but does not appear to reduce DTG or BIC susceptibility. F121C is an exceedingly rare mutation that has been reported to cause high-level resistance to RAL, EVG, and CAB but low-level reduced susceptibility to DRG and BIC.",F121Y
128T,Accessory,"A128T is a relatively nonpolymorphic possible INSTI-selected mutation, which does not appear to reduce INSTI susceptibility",A128T
138D,Other,E138D is a polymorphism that occurs in 1% to 2% of viruses from INSTI-naive patients. It does not appear to be selected by INSTIs or to reduce INSTI susceptibility.,E138D
138KAT,Major,"E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A.",E138KAT
140R,Major,G140R is a nonpolymorphic mutation reported in n macaques receiving CAB pre-exposure prophylaxis and in a person receiving simplification therapy with RPV/CAB. It reduces CAB susceptibility by 7-fold.,G140R
140SAC,Major,"G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. Their appearance may suggest that a Q148 mutation may have once been present.",G140SAC
142T,Accessory,P142T is a rare nonpolymorphic mutation selected in vitro and in vivo by RAL. It usually occurs in combination with other INSTI-resistance mutations. Its effect on susceptibility has not been studied.,P142T
143CRH,Major,"Y143C/R/H are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce susceptibility to DTG, BIC, or CAB.",Y143CRH
143KGSA,Major,"Y143K/G/S/A are rare mutations that cause intermediate reductions in RAL susceptibility. When they occur in combination with other accessory mutations, they may also cause low-level reductions in EVG susceptibility.",Y143KGSA
145S,Major,P145S is a rare non-polymorphic mutation selected in vitro by EVG and rarely in patients receiving EVG. It causes high-level resistance to EVG but not to any other INSTI.,P145S
146P,Major,Q146P is a rare non-polymorphic mutation selected in vitro by EVG which causes low-to-intermediate reductions in EVG and CAB susceptibility.,Q146P
147G,Major,"S147G is a non-polymorphic mutation selected primarily in patients receiving EVG and less commonly in patients receiving RAL and DTG. It moderately reduces EVG susceptibility. It does not reduce RAL, DTG, or BIC susceptibility.",S147G
148HKR,Major,"Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with near complete resistance to RAL and EVG, high-levels of reduction in CAB susceptibility, and intermediate reductions in DTG and BIC susceptibility. The presence of Q148H/K/R plus two INSTI DRMs is usually associated with high-level reductions in susceptibility to all INSTIs.",Q148HKR
148N,Major,"Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with near complete resistance to RAL and EVG, high-levels of reduction in CAB susceptibility, and intermediate reductions in DTG and BIC susceptibility. The presence of Q148H/K/R plus two INSTI DRMs is usually associated with high-level reductions in susceptibility to all INSTIs. Q148N is a rare INSTI-selected mutation that causes ~3-fold reduced EVG susceptibility and may represent a reversion from Q148H or Q148K.",Q148N
149A,Accessory,"G149A selected in vivo by DTG in RAL experienced patients. It appears to have no effect by itself but in combination with mutations at positions 140 and 148, it reduces DTG susceptibility.",G149A
151A,Accessory,V151A is an extremely rare non-polymorphic mutation associated with minimally reduced susceptibility to RAL and EVG.,V151A
151I,Other,"V151I is an accessory INSTI selected mutation that occurs in 1% to 5% of viruses from ARV-naive patients depending on subtype. Alone, it appears to have little or no effect on INSTI susceptibility.",V151I
151L,Major,V151L is an extremely rare non-polymorphic mutation that confers intermediate / high-level reduced susceptibility to RAL and EVG and low-level reduced susceptibility to DTG.,V151L
153YF,Accessory,"S153Y/F are rare non-polymorphic mutations selected in vitro by EVG, DTG, and BIC. S153Y/F reduce RAL, DTG, and possibly BIC susceptibility about 2-fold and EVG susceptibility about 4-fold.",S153YF
155H,Major,"N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility.",N155H
155ST,Major,"N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility. N155S/T are extremely rare non-polymorphic mutations selected in vitro by investigational INSTIs. They reduce RAL and EVG susceptibility somewhat less than does N155H.",N155ST
157Q,Accessory,E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility.,E157Q
163RK,Accessory,"G163R/K are polymorphic in subtype F viruses from ARV-naive patients but are otherwise non-polymorphic. They are common INSTI-selected mutations. Alone, they have little, if any, effect on INSTI susceptibility.",G163RK
230N,Other,S230N is a polymorphism that is not associated with reduced INSTI susceptibility.,S230N
230R,Accessory,"S230R is a non-polymorphic mutation selected by RAL, EVG, and DTG. It possibly causes low-level reductions in DTG susceptibility.",S230R
232N,Accessory,D232N is a common nonpolymorphic accessory mutation selected in patients receiving RAL and EVG.,D232N
263K,Major,"R263K is selected in vitro by EVG, DTG, and BIC, and in patients receiving DTG. It reduces DTG and BIC susceptibility about 2-fold and EVG susceptibility somewhat more.",R263K
